[ACHN] Achillion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.38 Change: 0.39 (9.77%)
Ext. hours: Change: 0 (0%)

chart ACHN

Refresh chart

Strongest Trends Summary For ACHN

ACHN is in the long-term down -81% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and resistant bacterial infections. The company?s drug candidates for treating chronic HCV infection comprise Sovaprevir, a NS3/4A protease inhibitor, which has completed a Phase IIa clinical trial; ACH-3102, a NS5A inhibitor that is in Phase IIa clinical trial; ACH-3422, a NS5B nucleotide polymerase inhibitor, which has completed preclinical studies; and ACH-2684, a NS3/4A protease inhibitor that has completed Phase Ia and Ib clinical trials. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, an antibacterial drug candidate that is delivered topically or locally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Fundamental Ratios
Shares Outstanding EPS-0.47 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-9
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.83% ROE-27.14% ROI
Current Ratio19.64 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities138.96 M Cash From Investing Activities-148.58 M Cash From Operating Activities-17.32 M Gross Profit
Net Profit-19.26 M Operating Profit-19.4 M Total Assets279.42 M Total Current Assets255.58 M
Total Current Liabilities13.01 M Total Debt610 K Total Liabilities13.41 M Total Revenue
Technical Data
High 52 week5.15 Low 52 week2.65 Last close3.1 Last change1.31%
RSI20.21 Average true range0.12 Beta0.8 Volume2.41 M
Simple moving average 20 days-9.36% Simple moving average 50 days-12.63% Simple moving average 200 days-13.92%
Performance Data
Performance Week-1.27% Performance Month-10.92% Performance Quart-26.37% Performance Half6.9%
Performance Year-26.01% Performance Year-to-date7.64% Volatility daily2.03% Volatility weekly4.55%
Volatility monthly9.32% Volatility yearly32.3% Relative Volume236.65% Average Volume1.22 M
New High New Low

News

2020-01-29 14:04:44 | $930 million sale of Blue Bell biopharma firm finalized

2020-01-28 07:12:23 | The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

2020-01-27 10:25:03 | Will Soliris, Ultomiris Drive Alexion's ALXN Q4 Earnings?

2020-01-08 07:48:12 | Apellis' APLS PNH Drug Betters Alexion's Soliris in Study

2020-01-02 09:49:02 | 4 Reasons Why Investors Should Buy Alexion ALXN in 2020

2019-12-20 11:46:51 | Achillion shareholders approve proposed $930M sale of company

2019-12-19 09:24:16 | Achillion Shareholders Approve Agreement to be Acquired by Alexion

2019-12-09 19:08:22 | Did Hedge Funds Drop The Ball On Achillion Pharmaceuticals, Inc. ACHN ?

2019-12-09 10:00:10 | Achillion Reports Positive Data from Phase 2 Study of Danicopan ACH-4471 in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

2019-12-07 11:31:04 | Why Is Achillion ACHN Down 2.8% Since Last Earnings Report?

2019-11-29 23:30:10 | Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.

2019-11-29 11:49:29 | 8 Stocks Paul Tudor Jones Continues To Buy

2019-11-27 12:15:05 | 5 Stocks That Pushed Russell 2000 ETF Higher

2019-11-22 10:42:00 | Moore Kuehn, PLLC Encourages Investors of SRC Energy, Inc. SRCI, Achillion Pharmaceuticals, Inc. ACHN, and Arotech Corporation ARTX to Contact Firm

2019-11-20 09:50:02 | Achillion's ACHN Danicopan Gets EMA's PRIME Tag for PNH

2019-11-19 07:30:00 | European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

2019-11-14 09:58:02 | Alexion ALXN Up 10 % YTD on Soliris & Ultomiris Strength

2019-11-11 07:30:00 | Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks

2019-11-07 16:55:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Continues Legal Inquiry Regarding the Buyout

2019-11-07 09:00:00 | Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies Is Fair to Shareholders - CISN, ACHN, VSI

2019-11-07 07:30:00 | Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update

2019-11-06 14:36:44 | Here is What Hedge Funds Think About Achillion Pharmaceuticals, Inc. ACHN

2019-11-06 13:35:00 | INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Transaction

2019-11-06 10:45:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders - AYR, WLH, ACHN

2019-11-06 09:07:20 | Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting

2019-11-05 14:35:00 | STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding Buyout

2019-11-04 16:04:44 | Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – LPT, CISN, IPHS, ACHN

2019-11-04 14:55:00 | Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European Media Enterprises Ltd., Digital Realty Trust, Inc., Fitbit, Inc., MutualFirst Financial, Inc., and Ra Pharmaceuticals Inc.

2019-11-01 18:00:00 | STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Buy Out

2019-11-01 14:10:00 | Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies Is Fair to Shareholders – RARX, ACHN, IPHS, CISN

2019-10-30 15:45:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Reminds Investors of the Following Investigation

2019-10-30 10:43:57 | Healthcare ETFs Win in October: Here's Why

2019-10-29 15:02:39 | SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations

2019-10-28 12:30:45 | MERGER ALERT – ACHN, RARX, and IPHS: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies

2019-10-24 13:59:52 | SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Acquisitions

2019-10-24 11:26:00 | ACHILLION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Achillion Pharmaceuticals, Inc. - ACHN

2019-10-24 11:09:03 | The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

2019-10-24 09:35:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CISN, IPHS, ACHN

2019-10-23 16:35:22 | MERGER ALERT – ACHN, JAG, and ROAN: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies

2019-10-23 14:00:00 | ACHN, ROAN, VSI: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger

2019-10-23 11:26:03 | Alexion ALXN Beats on Q3 Earnings, Lifts 2019 Guidance

2019-10-23 10:10:02 | Biotech ETFs Surge on a Flurry of Positive News

2019-10-23 09:45:01 | Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

2019-10-22 15:07:00 | Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – IPHS, ACHN, RARX, TSG

2019-10-21 09:33:01 | Alexion Gets FDA Approval for Label Expansion of Ultomiris

2019-10-19 10:30:00 | INVESTOR ALERT: Monteverde & Associates PC Is Investingating The Merger

2019-10-18 16:50:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?

2019-10-18 12:00:00 | SHAREHOLDER INVESTIGATION ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - RARX, DOVA, ACHN